HC Wainwright Issues Optimistic Estimate for NRIX Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIXFree Report) – Stock analysts at HC Wainwright raised their Q3 2025 earnings estimates for Nurix Therapeutics in a report released on Monday, July 14th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.68) per share for the quarter, up from their prior estimate of ($0.76). HC Wainwright has a “Buy” rating and a $34.00 price objective on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Nurix Therapeutics’ Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($2.76) EPS, Q1 2026 earnings at ($0.91) EPS, Q2 2026 earnings at ($0.94) EPS, Q3 2026 earnings at ($0.97) EPS, Q4 2026 earnings at ($0.91) EPS and FY2026 earnings at ($3.73) EPS.

Nurix Therapeutics (NASDAQ:NRIXGet Free Report) last posted its quarterly earnings data on Wednesday, July 9th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.27. The company had revenue of $44,056 billion during the quarter, compared to analysts’ expectations of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%.

NRIX has been the subject of a number of other reports. Stephens reiterated an “overweight” rating and issued a $30.00 target price on shares of Nurix Therapeutics in a research report on Thursday, July 10th. Needham & Company LLC reiterated a “buy” rating and issued a $27.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. UBS Group reduced their target price on shares of Nurix Therapeutics from $30.00 to $26.00 and set a “buy” rating for the company in a research report on Thursday, July 10th. Wall Street Zen upgraded shares of Nurix Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 21st. Finally, Wells Fargo & Company reduced their target price on shares of Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, April 9th. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $29.31.

View Our Latest Stock Analysis on NRIX

Nurix Therapeutics Stock Performance

NASDAQ:NRIX opened at $12.42 on Wednesday. The company has a fifty day moving average of $11.39 and a two-hundred day moving average of $13.70. The stock has a market capitalization of $949.51 million, a PE ratio of -4.76 and a beta of 2.15. Nurix Therapeutics has a fifty-two week low of $8.18 and a fifty-two week high of $29.56.

Institutional Investors Weigh In On Nurix Therapeutics

A number of hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. grew its holdings in shares of Nurix Therapeutics by 9.5% in the first quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company’s stock valued at $6,029,000 after purchasing an additional 44,002 shares during the period. Rhumbline Advisers boosted its stake in Nurix Therapeutics by 7.0% during the first quarter. Rhumbline Advisers now owns 110,488 shares of the company’s stock worth $1,313,000 after buying an additional 7,255 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Nurix Therapeutics by 8.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company’s stock worth $1,895,000 after buying an additional 12,817 shares during the period. Millennium Management LLC boosted its stake in Nurix Therapeutics by 106.2% during the first quarter. Millennium Management LLC now owns 874,399 shares of the company’s stock worth $10,388,000 after buying an additional 450,262 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Nurix Therapeutics by 11.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company’s stock worth $593,000 after buying an additional 5,286 shares during the period.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 6,198 shares of the company’s stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.33, for a total value of $70,223.34. Following the completion of the sale, the chief financial officer owned 33,724 shares of the company’s stock, valued at approximately $382,092.92. This represents a 15.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Gwenn Hansen sold 3,377 shares of the company’s stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the completion of the sale, the insider directly owned 61,516 shares of the company’s stock, valued at $707,434. This represents a 5.20% decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,013 shares of company stock valued at $137,096 in the last three months. 7.40% of the stock is currently owned by insiders.

Nurix Therapeutics Company Profile

(Get Free Report)

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Featured Articles

Earnings History and Estimates for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.